Clinical Trials List
2021-02-01 - 2026-03-18
Phase III
Not yet recruiting2
Recruiting7
Terminated1
ICD-10C34.90
Malignant neoplasm of unspecified part of unspecified bronchus or lung
ICD-10C34.91
Malignant neoplasm of unspecified part of right bronchus or lung
ICD-10C34.92
Malignant neoplasm of unspecified part of left bronchus or lung
ICD-10C7A.090
Malignant carcinoid tumor of the bronchus and lung
ICD-10Z51.12
Encounter for antineoplastic immunotherapy
ICD-9162.9
Malignant neoplasm of bronchus and lung, unspecified
-
Trial Applicant
-
Sponsor
-
Trial scale
Multi-Regional Multi-Center
-
Update
2026/04/01
Investigators and Locations
The Actual Total Number of Participants Enrolled
0 Recruiting
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
- Chi-Lu Chiang 未分科
- Yung-Hung Luo 未分科
- Heng-Sheng Chao 未分科
- 蕭慈慧 未分科
- Hsu-ching Huang 未分科
- YEN-HAN TSENG 未分科
- Chia-I Shen 未分科
The Actual Total Number of Participants Enrolled
0 Not yet recruiting
Co-Principal Investigator
- Wen-Cheng Chang 無
- 柯皓文 無
- Shih-Hong Li 無
- Chien-Ying Liu 無
- Chih-Liang Wang 無
- Ping-Chih Hsu 無
- Chih-Hung Chen 未分科
- 枋岳甫 無
- 邱立忠 無
- Chih-Hung Chen 無
- Chih-Hsi Kuo 無
- 林定佑 無
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
- JENG-SEN TSENG 未分科
- KUO-HSUAN HSU 未分科
- YEN-HSIANG HUANG 未分科
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
- 王馨儀 未分科
The Actual Total Number of Participants Enrolled
0 Recruiting
The Actual Total Number of Participants Enrolled
0 Recruiting
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
- Chia-Hsiang Li 未分科
- 廖偉志 未分科
- Chih-Yen Tu 未分科
- 陳鴻仁 未分科
The Actual Total Number of Participants Enrolled
0 Not yet recruiting
The Actual Total Number of Participants Enrolled
0 Terminated
Condition/Disease
Objectives
Test Drug
Active Ingredient
Dosage Form
Dosage
Endpoints
Inclution Criteria
The Estimated Number of Participants
-
Taiwan
60 participants
-
Global
1210 participants
